Medical device and MedTech insights, news, tips and more

Invenio Imaging Receives CE Mark to Detect Cancer at the Time of Surgery using Artificial Intelligence

May 25, 2022


Invenio Imaging, the leader in intraoperative fresh tissue imaging, announced the CE Mark for the NIO Glioma Reveal image analysis module. NIO Glioma Reveal is based on deep learning and allows neurosurgeons to identify areas of cancer infiltration in patients undergoing primary treatment of a diffuse glioma. With the CE mark, neurosurgeons in the European Union can now use NIO Glioma Reveal to inform intraoperative decisions.

“By streamlining intraoperative tissue imaging, the NIO Laser Imaging System allows the imaging of multiple samples from the resection cavity. The NIO Glioma Reveal image analysis module now adds immediate decision support”, says Chris Freudiger, PhD, co-founder and CTO of Invenio Imaging.

“Glioma Reveal provides cancer detection where we really need it, dramatically improving brain tumor surgery”, says Prof. Dr. Jürgen Beck, Chair of Neurosurgery at the University of Freiburg.

“Applying reliable artificial intelligence to digital pathology appears to me, as a surgeon, to be the missing piece in the puzzle of rapid intraoperative histology-based decision-making”, says Asst. Prof. Dr. Volker Neuschmelting, Vice-Chair of Neurosurgery at the University of Cologne. 

“The NIO Laser Imaging System can also be combined with other important imaging techniques such as 5-ALA fluorescence to further improve brain tumor detection during surgery”, says Prof. Dr. Georg Widhalm, neurosurgeon at the University of Vienna.

Invenio will launch NIO Glioma Reveal at the upcoming Annual Meeting of the German Society of Neurosurgery (DGNC) in Cologne from 29 May – 01 June 2022.

*NIO Glioma Reveal is available “For Research Use Only” in the United States, not for use in diagnostic procedures.

About Invenio Imaging Inc.

Invenio Imaging is a medical device start-up based in Santa Clara, CA dedicated to advancing the care of cancer patients by combining intraoperative fresh tissue imaging with artificial intelligence. Our technology, the NIO Laser Imaging System, has been used in over 2500 procedures at major cancer centers in the US and in Europe. In 2021 Invenio received a Medical Design Excellence Award, was selected to be a Rosenman Innovator, and received CE Mark to commercialize in Europe.

See Full Press Release at the Source: Invenio Imaging Receives CE Mark to Detect Cancer at the Time of Surgery using Artificial Intelligencees for 510(k) Clearance for Two New Products

Press Release by: Invenio Imaging

Legacy MedSearch has more than 35 years of combined experience recruiting in the medical device industry. We pride ourselves on our professionalism and ability to communicate quickly and honestly with all parties in the hiring process. Our clients include both blue-chip companies and innovative startups within the MedTech space. Over the past 17 years, we have built one of the strongest networks of device professionals ranging from sales, marketing, research & , quality & regulatory, project management, field service, and clinical affairs.

We offer a variety of different solutions for hiring managers depending on the scope and scale of each individual search. We craft a personalized solution for each client and position with a focus on attracting the best possible talent in the shortest possible time frame.

Are you hiring?
Contact us to discuss partnering with Legacy MedSearch on your position.

More insights

March 7, 2024
FDA Clears Dexcom’s First Over-the-Counter Continuous Glucose Monitor
Learn More
March 1, 2024
FDA greenlights Boston Scientific’s Novel Drug-Coated Balloon for Coronary In-Stent Restenosis
Learn More
February 21, 2024
Sparrow BioAcoustics Launches Software That Turns a Smartphone into a Stethoscope 
Learn More

Begin your legacy now. We are your medtech and medical device talent advisory firm.